Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

AstraZeneca

Status and phase: Terminated; Phase 1

Conditions: Lymphoma

Treatments: Drug: AZD4877

Study type: Interventional

Funder types: Industry

Identifiers

NCT00460460

D2782C00002

Details and patient eligibility

About

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Enrollment: 75 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with AML, a certain type of ALL, NHL and MM
• certain types of cancer of the lymph nodes
• certain types of leukemias (blood cancers)
• disease has or will fail with other treatments
• relatively good overall health other than your cancer

Exclusion criteria

• poor bone marrow function (not producing enough blood cells)
• serious heart conditions
• poor liver or kidney function

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)